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Abstract   
 
 
Purpose:  The purpose of this study was to determine the incidence of Methcillin 
Resistant Staph Aureus (MRSA) infections among the Native American populations of 
La Push Washington. The study also examined the treatment of these infections and 
assessed whether they were treated in accordance with national and state guidelines.  
 
Methods:  A chart review was done over all the cases of cellulitis and abscess recorded 
from 2003 until 2008. The charts were examined for cases of soft tissue Community 
Acquired MRSA (CA-MRSA). The data was then assessed for prevalence of CA-MRSA, 
its reoccurrence, treatment, and the effectiveness of treatment.  
 
Results:  The data revealed that there were 42 patients with soft tissue CA-MRSA. There 
appears to be a trend of increased cases which reflects the trend for the rest of the state of 
Washington.  Most of these patients were treated by national standard with incision and 
drainage as well as with antimicrobial therapy when appropriate. The data also showed a 
great number of recurrent infections despite being treated appropriately.   
 
Conclusion:  CA-MRSA is an increasing problem in healthcare. Appropriate treatment 
and patient education are key factors in overcoming these infections. More research is 
needed to determine if there is a specific cause for the relatively high rate of reoccurrence 
in soft tissue MRSA infections in La Push Washington. The rate of original infection 
seems to follow the trend of the rest of the state, but a comparison of reinfection was not 
obtained from Washington State.  
 
Keywords:  MRSA, Methicillin-Resistant Staphylococcus Aureus, Native American, 
Quileute.  
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Introduction and Background: 
Methicillin-Resistant Staphylococcus aureus (MRSA) is a staph infection that is resistant 
to most of the broad spectrum antibiotics used to treat it. It is a gram positive cocci, 
appearing as a cluster of grapes beneath the microscope. Originally, infection with 
MRSA typically occurred in hospitalized patients, known as health care-associated 
MRSA infection (HC-MRSA). It has since spread to infect healthy individuals in the 
community and is known as community acquired-MRSA (CA-MRSA). The current 
definition of MRSA states that it must have an oxacillin minimum inhibitory 
concentration (MIC) >4mcg/ml.  Isolates to oxacillin or methicillin are also resistant to 
all beta-lactam agents including oxacillin, dicloxacillin, and cefazolin.8  By the Center for 
Disease Control’s (CDC) definition, CA-MRSA infection is classified as community-
associated in individuals who have not been hospitalized or undergone a medical 
procedure within the past 12 months.5    
 
Currently, MRSA accounts for 64 percent of S. aureus in American intensive care units13.  
A recent national study estimated that 85 percent of serious invasive MRSA infections 
are hospital associated and 15 percent occur in the community.13   
 
The resistance of MRSA to beta-lactam antibiotics is due to the presence of the mecA 
gene sequence. The mecA gene produces transpeptidase PBP2a (penicillin-binding 
peptide) that decreases the bacterial affinity of the beta-lactam antibiotics. The mecA 
gene is a subset of a larger SCCmec gene that is responsible for the differences seen in 
HA-MRSA and CA-MRSA bacteria.  
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CA-MRSA has a propensity for skin and soft tissue (up to 96% of cases)3, with furuncles 
(superficial skin abscesses arising from hair follicles) being by far the most common.10 
CA-MRSA also causes folliculitis, impetigo, cellulitis, carbuncles, paronychia, deep 
subcutaneous abscesses and necrotizing fasciitis. Characteristics of MRSA-associated 
skin lesions include localized necrosis, which are often mistaken for spider bites9. Skin 
infections associated with MRSA often have a ‘scalded skin appearance’, with the 
superficial layers of skin tending to flake away. These blistered appearing wounds often 
have a very tender base.  Without other signs of infection, a biopsy is needed to 
determine the presence of a staph infection.  
 
Special testing has been evolved to improve detection with cultures. An erythromycin-
induction test, or D-test, should always be performed with staphylococcal sensitivities to 
reveal inducible clindamycin resistance among CA-MRSA.  
 
In most cases, incision and drainage (I & D) is sufficient to treat lesions. These lesions 
should undergo I& D if there is fluctuant or purulent skin and/or soft tissue. Specimens 
from these wounds should then be sent for culture and susceptibility testing 8.  Adjunctive 
antibiotics are recommended with: complicated abscesses (with fever, lymphangitis, or 
significant surrounding cellulitis), rapidly progressive or severe local disease, abscess 
diameter greater than 5 cm, comorbid conditions or immunosuppression 9. 
 
The next area of concern in proper treatment of MRSA is associated with antimicrobial 
selection. Because the prevalence of CA-MRSA is so high, empirical treatment with 
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penicillins or cephalosporins are often insufficient.2  Baseline susceptibility testing is the 
most valuable tool in treating suspected MRSA infection8. Other concerns would include 
individual patient circumstances, such as comorbid conditions and concurrent 
medications. Some antibiotics that may be useful in treatment include older agents such 
as clindamycin, trimethoprim-sulfamethaozazole (TMP-SMX), and minocycline. New 
agents such as linezolid should be used only when an allergy to the older agents is 
present. The older agents have been rigorously tested in clinical trials and have been 
found to be effective8.  Fluoroquinolones are a poor choice since resistance develops 
rapidly. Follow-up re-evaluation after 24-48 hours is important after beginning empiric 
antibiotic therapy, as a culture may have been grown during that time interval. Patient 
response should be used to guide therapy. Patients with extensive systemic involvement 
or severe soft tissue infection may warrant parenteral therapy which would include 
Vancomycin.  This antibiotic has been found effective, but should be reserved for use 
only in severe circumstances.  In the event the patient is unable to tolerate vancomycin, 
the FDA has approved daptomycin, tigecycline, and quinupristin-dalfopristin.  
 
Many patients who develop a MRSA infection will often harbor the bacteria in other 
areas of the body as well. Nasal application of mupirocin may be beneficial in some 
patients to prevent recurrence of infection, however, recolonization is still likely to occur 
shortly.2 Topical antiseptics such as chlorhexidine, povidone iodine (Hibicleans) can also 
be helpful in cleansing surface skin to prevent reinfection .9  
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In an effort to better understand CA-MRSA, a study was done in a community which 
seemed to have a great number of soft tissue infections. Located in Clallam County, 
Washington, is a small rural clinic which serves the Native American Quileute tribe. The 
practioners of this clinic felt they noticed an increased number of cases of CA-MRSA 
infections. The CDC reports that Native Americans are a group most commonly affected 
with CA-MRSA5. This study’s goal was to assess if the infection rate at this clinic is 
abnormally high and if it is being treated effectively.   
 
Methods: 
After acquiring approval from both the Quileute Tribal Clinic administration and the 
Pacific University Institutional Review Board for Protection of Human Subjects (IRB), a 
chart review was conducted at the Quileute tribal clinic in La Push, Washington. The 
tribal billing database was used to conduct a Search of  ICD-9 codes with a diagnosis of 
cellulitis or abscess. The charts were collected and examined for positive MRSA culture 
results. The search covered a time period from January 2003 until June 2008.  From each 
of the charts the following data was collected: sex, age, site of infection, date of 
treatment, recurrent infections, and treatment results. Appendix A shows a copy of the 
IRB proposal as well as a sample of the collection form used. Upon collection of data, 
patient identifiers were removed. Data was also obtained from publications of the 
Washington State Health Department to serve as an indicator of the prevalence of CA-
MRSA in other areas of Washington. The demographics of the patients were tabulated to 
investigate whether one population was being more strongly affected than any other. The 
data were categorized by treatment modality for analysis. The methods were examined to 
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see if the majority of patients were being treated appropriately as specified by the 
Washington Sate Health Department as well as CDC guidelines. A measurement of how 
effective these treatments were was attempted. Effectiveness was determined by patient 
recovery time as well as reduction or elimination of recurrent infections.  
 
Results:  
 There were 82 patients with the diagnosis of cellulites and/or abscess which could be 
associated with CA-MRSA skin infections. Chart reviews for cellulitis revealed that of 
the 82 patients identified, 52 had skin lesions that were cultured, with 46 of these cultures 
being MRSA positive and the remaining 6 cultures revealing Methicillin susceptible 
Staphylococcus aureus (MSSA) (Table 1).  
 
Table 2 shows the demographics of the patients treated for MRSA between 2003-2008. 
Figure 1, shows the distribution of CA-MRSA soft tissue infection by year. It 
demonstrates an increase in the number of patients infected from 2004 until 2007. Data 
for 2008 was only obtainable prior to the month of June, so the results were extrapolated 
for the entire year. It may be possible that there will be more cases of CA-MRSA later on 
in the year. 
 
A collection of infection rates for the entire state of Washington was not available. 
However, the state has posted an estimate for the rates of infection for the central portion 
of the state (Figure 2). Figure 3, demonstrates the trends in the state of Washington for 
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2003-2004. Figure 4 shows the trends of infection for La Push, Washington from 2003 to 
2007.   
 
A list of treatment modalities utilized revealed that there were two antibiotics recorded 
for use in these CA-MRSA cases: cephalexin and TMP-SMX. Figure 5 shows the 
methods of treatment for soft tissue infections. Four cases were treated with cephalexin 
alone and one was treated with both cephalexin and incision and drainage (I & D). Eleven 
of these cases were treated with TMP-SMX alone, while the majority of cases - 23 - were 
treated with both TMP-SMX and I & D. There were no antibiotics charted for the 
remaining 7 cases. Six cases were treated with I & D only. There was only one case of 
MRSA that was not treated with I & D or antimicrobials, it was charted that the lesion 
was draining it seemed to be healing well on its own, and that it seemed to be healing 
without antibiotic treatment. 
 
Table 3 was obtained from the state of Washington Health Department and depicts the 
percentages of infections within the state, distributed by region. Table 4 provides a 
similar comparison representing the percentages of infections for La Push Washington by 
itself. 
 
Table 5 represents the frequency of infection by location as listed by body area. 
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Figure 6 shows the numbers of recurrent infection distributed by the number of isolated 
reinfection. To better appreciate the relationship between recurrence and treatments, 
Figure 7 was tabulated.  
 
Discussion: 
The data collected from the Quileute clinic reveal that there has been an increase in CA-
MRSA soft tissue infections from 2003 through 2007. The data for 2008 was extrapolated 
to show a trend and should not be considered a true reporting for 2008.  From 2003 to 
2007, the infection rate in La Push jumped from 1.4 individuals per 1000 to 29 
individuals per 1000.  In the state of Washington, the infection rate jumped from 168 
individuals per 1000 in 2000 to 326 individuals per 1000 in 2003.  Although the time 
periods examined differed, the trends of the two populations demonstrate an increase in 
infected cases.  Data from the state of Washington evidences a statewide increase in the 
number of CA-MRSA cases, suggesting that La Push is not the only community 
struggling with this health issue. Tables 3 and 4 compare the infection rates between La 
Push and the entire state of Washington in percentages of infections. 
 
The number of infections relative to age and sex seem to be evenly dispersed. Although 
Table 2 shows that there are more individuals between the age of 18 and 50 with MRSA 
infections, this is to be expected because this age group makes up the greatest population 
in the area. The data does suggest that there are more women infected than men, but the 
reasons for this are speculative.  
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It was thought to be useful to examine how the current treatment of CA-MRSA at the 
tribal clinic compared to national and Washington State clinical guidelines. 
According to the CDC, I & D must be emphasized as a primary treatment of fluctuant 
abscesses and should be performed whenever possible 4. For mild uncomplicated 
abscesses, I & D without the use of antimicrobials can be a reasonable treatment option. 
In this paper’s population, 6 cases were treated in this way.   
 
Adjunctive antimicrobial therapy may be useful in decreasing spread by sterilizing 
ongoing wound drainage. This was the most practiced method at the clinic. Antimicrobial 
therapy alone (topical or oral) without I & D is not recommended for treatment of 
fluctuant abscesses.4   In recent studies, penicillin and  cephalosporin medications 
(including cephalexin) have not been effective in treating CA-MRSA6. The CDC has 
obtained reports that clindamycin has been effective in treating MRSA. If the infection 
does not improve with the use of clindamycin, then treatment should be reassessed as at 
times MRSA strains are resistant to this antibiotic.  
 
While tetracycline derivatives are often effective in treatment of severe staph infections, 
they have not been found to be effective in the treatment of MRSA. And while TMP-
SMX is not an FDA approved medication for treatment of CA-MRSA, clinical trials have 
found it to be the most effective medication at treating MRSA infections. A California 
study found that when combined with I & D, TMP-SMX was effective in 50% of its 
patients.5 The California study did not analyze, nor did it have appropriate resources to 
analyze whether a lesion was fluctuant or not, as this information was not recorded.  
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In reviewing Figure 5, eleven cases used TMP-SMX only, and 4 cases were treated with 
only cephalexin. The primary method of treatment of CA-MRSA used at the tribal clinic 
was a combination of TMP-SMX and I & D.  Further analysis is required to determine if 
these cases were treated appropriately or not. The CDC and American Medical 
Association recommends I & D as the first line treatment for CA-MRSA soft tissue 
infection.5 In the data collected there were 6 patients treated by this method. Only one 
patient was treated without use of either antimicrobials or I & D.  
 
After examining the number of recurrent infections (Figure 6) it was noted that there 
were a significant number of recurrent infections. Of the forty-six patients who had a 
MRSA soft tissue infection, over half (twenty-four) had a recurrent infection requiring 
another treatment.  
 
Figure 7 indicates how the twenty-four individuals with recurrent soft tissue infections 
were treated upon their first diagnosis of CA-MRSA. The number of patients treated with 
TMP-SMX and I & D is highest, however, because this is also the most common method 
of treatment, it is unknown if this is due to ineffectiveness or simply a reflection of the 
number of patients treated with this method. The data shows that despite being treated by 
the recommended methods, these patients are still having recurrent infections with CA-
MRSA. None of the treatments with recurrent infections stand out as being less effective 
when considering the initial number of patients treated by that method. To thoroughly 
evaluate the effectiveness of these treatments, an equal number of patients would need to 
be treated by each method and the results evaluated.  Such research is outside the scope 
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of this paper.  There are many factors which may affect the ability of a patient to recover 
from a soft tissue MRSA infection including compliance to medications, level of hygiene, 
and appropriate dressing changes, to name a few. This study was not detailed enough to 
determine the effect of these variables on recurrence. 
 
Conclusion:  
CA-MRSA is an increasing problem in healthcare. Appropriate treatment and patient 
education are key factors in overcoming these infections. More research is needed to 
determine if there is a specific cause for the relatively high rate of reoccurrence in soft 
tissue MRSA infections in La Push, Washington. 
 21 
 
Tables: 
 
 
 
 
 
 
 
 
 
 
Table 1. Results of cultures from cellulitis or abscess.  
 
 
 
Age Years <18  19-50 >51 Totals 
Male 6 10 3 19 
Female 2 17 8 27 
Total 8 27 11 46 
 
Table 2. Demographics of patients with CA-MRSA treated in the Quileute Clinic. 2004-
June 2008. 
 
 
 
Table 3.  Data taken from Washington State Health Department Summary 2003.14 
 
 
Culture Results  (n=82) # isolates 
Methcillin Resistant Staph Aureus (MRSA) 46 
Methcillin Susceptible Staph aureus (MSSA) 6 
Cultures not done 30 
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 La Push 
Year N % 
2003 1 .13 
2004 4 .56 
2005 6 .83 
2006 10 1.39 
2007 21 2.92 
 
Table 4.  Depiction of percentage of patients with CA-MRSA in La Push, WA. 
 
 
Location of Soft tissue infection Number of infections 
Face and Neck 4 
Upper extremity (including fingers) 9 
Lower extremity (including toes 25 
Trunk 25 
Buttocks 11 
Unspecified 1 
 
Table 5. Sites of Recorded CA-MRSA soft tissue infection (including recurrent 
infection) in La Push, WA. 
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Figures: 
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Figure 1. Number of cases of CA-MRSA Soft tissue infections, in the Quileute tribal 
clinic by year. (*2008 cases were extrapolated based on infection rate up until June of 
2008) 
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Figure 2.    Source: Washington State Department of Health 13. Region 7 Central 
Washington 
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Figure 3. Washington two year trend. From Washington State Health department.11 
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Figure 4.  La Push five year trend. 
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Figure 5. Treatment selected for patients with CA-MRSA soft tissue infections in La 
Push 
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Figure 6. Number of times patients in La Push that were treated for Soft tissue CA-
MRSA. 
 
 
 
 27 
Recurrence in association with treatment
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Figure 7. Number of recurrent infections compared to initial treatment in La Push. 
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Appendix A:  
PACIFIC UNIVERSITY INSTITUTIONAL REVIEW BOARD PROPOSAL  
For Faculty and Student Research  
 
 
 
 
 
 
TITLE 
A study on the prevalence of Methicillin-Resistant Staphylococcus Aureus 
in the Native American population of La Push, Washington. 
 
INVESTIGATORS   
 
Principal Investigator:    
Alexaus Toland 
Pacific University 
Physician Assistant Program 
(801)824-2161 
tola5536@pacificu.edu 
 
Faculty Advisor: 
Jon Gietzen 
Pacific University 
Physician Assistant Program 
(503) 352-7310  
jongietzen@pacificu.edu 
 
1. ABSTRACT AND PURPOSE 
 
The purpose of this study to determine the incidence of MRSA infections 
among the Native American populations and then compare it to the 
national and, if available, state rates of infection. The study will also 
examine the treatment of these infections and assess whether they are 
treated in accordance with national guidelines.  
 
2. PARTICIPANTS 
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Target Population This study will target the Native Americans with MRSA 
within the population of La Push Washington. Anticipated sample size will 
be 50. 
  
Recruitment  
No recruitment is necessary for this study.  
 
Exclusionary Criteria The data excluded would be patients that were not 
of the Native American population. 
 
3. MATERIALS AND MEASURES 
 
The Quileute clinic’s database will be used to obtain a list of patients 
diagnosed with MRSA lesions within the last 4-5 years. The patient’s 
charts will be used to collect data.  The data assessed will be tabulated in 
Excel the name, sex, age, date of infection, site of infection, treatment and 
results of treatment. Effective treatment will be characterized by the 
resolution of MRSA infected lesion. 
   
4. DESIGN AND PROCEDURE 
 
A list of patients with positive MRSA wound cultures will be obtained from 
the clinic’s existing database. Each of these charts will be examined for 
the following data; sex, age, site of infection, date of treatment, recurrent 
infections, and treatment results. The age, sex, and site of infection may 
affect the patient’s ability to recover from infection. The date of treatment 
is relevant for the length of time the treatment was used. Recurrent 
infections may signify how effective treatment was. Upon successful 
collection of data patient identifiers will be removed. No patient identifiers 
of name or ID number will be used in the data presented, it is only used to 
ensure appropriate data gathering in providing complete collection of data 
and preventing duplicate data collection. The results of the collected data 
will be tabulated and will be compared to the infection rates of the nation 
and if available the infection rates of the state of Washington. Treatment 
methods will also be examined for effectiveness. Effectiveness will be 
determined the patient’s recovery time, and by lack of or decrease in 
recurrent infections. The treatments used will be compared to national 
guidelines for treating MRSA infections.  
 
 
Location Data will be obtained at the Quileute clinic in La Push 
Washington 
 
Resources   It is not anticipated that there will be any funding required for 
this research.   
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Dates of the Study Data will be obtained via chart review from July 14, 
2008 until Aug 8, 2008, using data from 2003 to 2008. The data from 2003 
and 2004 will be compared to data collected by the state of Washington. 
 
5. RISKS TO PARTICIPANTS 
 
This is a retrospective study. The subjects should not be exposed to any 
risk. Other than the risk of accidental breach of confidentiality of PHI.  
 
6. BENEFITS TO PARTICIPANTS 
 
There is no direct benefit to any of the individuals tabulated in the study. 
 
7. COMPENSATION 
 
The individuals included in this study will not be compensated in any way, 
they will not receive any monetary compensation for being included.  
 
8. CONFIDENTIALITY 
 
While the information from the chart review is being gathered the patients 
will be identified by their clinic ID number. The chart reviews will be done 
only by the principle investigator who will also be responsible for ensuring 
patient confidentiality. This will be to prevent duplication or loss of 
information which may skew the study. The name and other private 
information will not be needed for this chart review. The age, gender ,lab 
results, site of infection, date of service or treatment, duration of treatment, 
treatment received, recurrent infections and effectiveness of treatment will 
all be data used in the study but none of which will be linked with any 
patient identifiers once the information is gathered. To reduce the chance 
of a breach of confidentiality the clinic ID number will be separated from 
the data and deleted at the earliest possible time after the data has been 
collected.  
 
 
9. WITHDRAWAL FROM THE STUDY 
 
This is not applicable since the study is archival.  
 
 
SIGNATURES OF INVESTIGATORS 
 
_______________________________ 
Alexaus Toland PA-S 
Principal Instigator  
Pacific University 
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_______________________________ 
 
Jon Gietzen PA-C 
 Faculty Advisor 
Pacific University  
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Appendix A: Measures 
Patient 
ID 
number 
Age Gender Lab 
result 
MRSA+ 
Date of 
Infection 
Site of 
infection 
Date of 
Treatment/ 
Length 
time of TX. 
Treatment   Results of 
Treatment 
Recurrent 
infections 
          
          
          
 
 
Appendix B: Recruitment Materials 
Not applicable 
 
Appendix C: Approval Letter from Outside Agency 
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